Care H1 2023 profit up 45% to SAR 104.1 mln; Q2 at SAR 47.8 mln

Care H1 2023 profit up 45% to SAR 104.1 mln; Q2 at SAR 47.8 mln

07/08/2023 Argaam Exclusive

View other reports

National Medical Care Co. reported a net profit of SAR 104.1 million for H1 2023, up 45% compared to SAR 72 million in the prior-year period.



Financials (M)

Item 6m 2022 6m 2023 Change‬
Revenues 427.97 506.59 18.4 %
Gross Income 128.24 171.22 33.5 %
Operating Income 81.12 112.58 38.8 %
Net Income 72.01 104.06 44.5 %
Average Shares 44.85 44.85 -
EPS (Riyals) 1.61 2.32 44.5 %

This was triggered by an 18% increase in revenue for the period due to higher business volume from the General Organization for Social Insurance (GOSI), Ministry of Health (MoH), and insurance segments, resulting in higher admissions, surgeries, and patient visits. Further, MoH billing had positive pricing impact as Care facilities achieved HIMSS accreditation.

 

Meanwhile, gross profit improved by 34% on lower cost of sale expenses as percentage of revenue and there was an increase in other income.

 

This came despite higher general and administrative costs and Zakat charge for the period.

 

The company’s Q2 2023 net profit rose 14% to SAR 47.80 million from SAR 42.01 million a year earlier, mainly due to higher revenue, lower cost of sales and improved gross profit margins.

 

On a sequential basis, Q2 net profit fell 15.1% from SAR 56.27 million, on lower revenue other income and gross profit as well as higher provisions for expected credit losses due to increased receivables and higher Zakat charge.

 



Current Quarter Comparison (M)

Compared With The
Item Q2 2022 Q2 2023 Change‬
Revenues 216.49 245.19 13.3 %
Gross Income 66.80 81.34 21.8 %
Operating Income 45.95 54.10 17.7 %
Net Income 42.01 47.80 13.8 %
Average Shares 44.85 44.85 -
EPS (Riyals) 0.94 1.07 13.8 %

Total shareholders’ equity, no minority interest, stood at SAR 1.32 billion by the end of H1 2023, down from SAR 1.15 billion in the year-earlier period.



Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2014 181.82 25.1 % 42.99 10.9 % 32.40 4.1 % 0.72
Q2 2014 179.74 26.4 % 56.27 77.0 % 31.06 40.0 % 0.69
Q3 2014 177.44 31.9 % 40.16 66.8 % 20.76 10.4 % 0.46
Q4 2014 194.99 18.8 % 37.85 12.9 % 10.28 (49.6 %) 0.23
Q1 2015 219.43 20.7 % 54.12 25.9 % 27.72 (14.4 %) 0.62
Q2 2015 227.86 26.8 % 64.96 15.4 % 42.29 36.1 % 0.94
Q3 2015 210.78 18.8 % 50.78 26.5 % 25.47 22.7 % 0.57
Q4 2015 220.60 13.1 % 50.34 33.0 % 35.24 242.7 % 0.79
Q1 2016 253.94 15.7 % 67.29 24.3 % 33.12 19.5 % 0.74
Q2 2016 259.77 14.0 % 84.30 29.8 % 59.29 40.2 % 1.32
Q3 2016 197.01 (6.5 %) 50.54 (0.5 %) 27.55 8.2 % 0.61
Q4 2016 189.94 (13.9 %) 4.86 (90.3 %) (69.69) (297.8 %) (1.55)
Q1 2017 202.44 (20.3 %) 41.19 (38.8 %) 15.54 (53.1 %) 0.35
Q2 2017 216.54 (16.6 %) 50.25 (40.4 %) 19.50 (67.1 %) 0.43
Q3 2017 208.34 5.8 % 46.97 (7.1 %) 27.00 (2.0 %) 0.60
Q4 2017 227.76 19.9 % 57.00 1072.0 % 23.26 133.4 % 0.52
Q1 2018 206.67 2.1 % 51.73 25.6 % 25.60 64.8 % 0.57
Q2 2018 199.05 (8.1 %) 49.59 (1.3 %) 20.26 3.9 % 0.45
Q3 2018 176.40 (15.3 %) 33.17 (29.4 %) 11.44 (57.6 %) 0.26
Q4 2018 181.69 (20.2 %) 32.02 (43.8 %) 4.87 (79.1 %) 0.11
Q1 2019 179.43 (13.2 %) 48.01 (7.2 %) 29.99 17.1 % 0.67
Q2 2019 169.94 (14.6 %) 38.26 (22.8 %) 13.81 (31.8 %) 0.31
Q3 2019 173.51 (1.6 %) 40.11 20.9 % 16.64 45.4 % 0.37
Q4 2019 185.52 2.1 % 39.27 22.6 % 19.64 303.2 % 0.44
Q1 2020 195.02 8.7 % 52.22 8.8 % 33.17 10.6 % 0.74
Q2 2020 186.04 9.5 % 58.87 53.9 % 25.78 86.6 % 0.57
Q3 2020 213.31 22.9 % 51.06 27.3 % 16.32 (1.9 %) 0.36
Q4 2020 214.60 15.7 % 61.73 57.2 % 22.00 12.0 % 0.49
Q1 2021 214.19 9.8 % 63.64 21.9 % 35.73 7.7 % 0.80
Q2 2021 202.49 8.8 % 57.77 (1.9 %) 30.74 19.2 % 0.69
Q3 2021 213.11 (0.1 %) 63.08 23.5 % 33.17 103.2 % 0.74
Q4 2021 215.59 0.5 % 61.98 0.4 % 36.71 66.9 % 0.82
Q1 2022 211.48 (1.3 %) 61.44 (3.5 %) 30.00 (16.0 %) 0.67
Q2 2022 216.49 6.9 % 66.80 15.6 % 42.01 36.7 % 0.94
Q3 2022 238.28 11.8 % 82.71 31.1 % 42.62 28.5 % 0.95
Q4 2022 251.69 16.7 % 78.74 27.0 % 55.45 51.0 % 1.24
Q1 2023 261.40 23.6 % 89.88 46.3 % 56.27 87.6 % 1.25
Q2 2023 245.19 13.3 % 81.34 21.8 % 47.80 13.8 % 1.07

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2014 21.26 % 20.31 % 15.06 %
Q2 2014 23.76 % 21.17 % 15.55 %
Q3 2014 24.60 % 20.97 % 14.88 %
Q4 2014 24.15 % 19.46 % 12.88 %
Q1 2015 24.42 % 18.66 % 11.64 %
Q2 2015 24.04 % 18.90 % 12.33 %
Q3 2015 24.35 % 19.23 % 12.40 %
Q4 2015 25.06 % 21.32 % 14.88 %
Q1 2016 25.56 % 21.44 % 14.91 %
Q2 2016 26.74 % 23.27 % 16.20 %
Q3 2016 27.11 % 23.91 % 16.67 %
Q4 2016 22.98 % 16.07 % 9.33 %
Q1 2017 21.30 % 14.58 % 7.82 %
Q2 2017 18.22 % 10.27 % 3.31 %
Q3 2017 17.53 % 9.96 % 3.19 %
Q4 2017 22.85 % 18.52 % 10.12 %
Q1 2018 23.97 % 20.17 % 11.24 %
Q2 2018 24.39 % 20.91 % 11.57 %
Q3 2018 23.64 % 20.41 % 10.10 %
Q4 2018 21.80 % 20.00 % 8.14 %
Q1 2019 22.10 % 21.08 % 9.04 %
Q2 2019 21.41 % 21.09 % 8.50 %
Q3 2019 22.48 % 21.77 % 9.27 %
Q4 2019 23.38 % 22.17 % 11.31 %
Q1 2020 23.46 % 22.32 % 11.50 %
Q2 2020 25.74 % 23.29 % 12.87 %
Q3 2020 25.83 % 22.00 % 12.17 %
Q4 2020 27.68 % 21.05 % 12.02 %
Q1 2021 28.41 % 20.86 % 12.06 %
Q2 2021 27.73 % 21.19 % 12.41 %
Q3 2021 29.16 % 23.15 % 14.41 %
Q4 2021 29.15 % 24.41 % 16.13 %
Q1 2022 28.99 % 23.58 % 15.50 %
Q2 2022 29.57 % 24.02 % 16.56 %
Q3 2022 30.95 % 24.24 % 17.16 %
Q4 2022 31.56 % 25.56 % 18.53 %
Q1 2023 32.87 % 26.57 % 20.29 %
Q2 2023 33.38 % 26.76 % 20.28 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2014 44.85 2.09 2.09 17.28
Q2 2014 44.85 2.29 2.29 17.97
Q3 2014 44.85 2.33 2.33 18.46
Q4 2014 44.85 2.11 2.11 18.69
Q1 2015 44.85 2.00 2.00 19.26
Q2 2015 44.85 2.25 2.25 18.66
Q3 2015 44.85 2.36 2.36 19.22
Q4 2015 44.85 2.91 2.91 20.01
Q1 2016 44.85 3.03 3.03 20.60
Q2 2016 44.85 3.41 3.41 21.16
Q3 2016 44.85 3.46 3.46 21.75
Q4 2016 44.85 1.12 1.87 20.18
Q1 2017 44.85 0.73 1.48 20.51
Q2 2017 44.85 (0.16) 0.59 20.93
Q3 2017 44.85 (0.17) 0.58 21.52
Q4 2017 44.85 1.90 1.93 21.98
Q1 2018 44.85 2.13 2.15 22.38
Q2 2018 44.85 2.14 2.17 21.83
Q3 2018 44.85 1.80 1.82 22.09
Q4 2018 44.85 1.39 1.39 22.23
Q1 2019 44.85 1.48 1.48 22.90
Q2 2019 44.85 1.34 1.34 22.20
Q3 2019 44.85 1.46 1.46 22.57
Q4 2019 44.85 1.79 1.79 23.03
Q1 2020 44.85 1.86 1.86 23.77
Q2 2020 44.85 2.12 2.12 22.34
Q3 2020 44.85 2.12 2.12 22.71
Q4 2020 44.85 2.17 2.17 23.12
Q1 2021 44.85 2.23 2.23 23.92
Q2 2021 44.85 2.34 2.34 23.60
Q3 2021 44.85 2.71 2.71 24.34
Q4 2021 44.85 3.04 3.04 25.07
Q1 2022 44.85 2.91 2.91 25.74
Q2 2022 44.85 3.16 3.16 25.67
Q3 2022 44.85 3.37 3.37 26.62
Q4 2022 44.85 3.79 3.79 28.17
Q1 2023 44.85 4.38 4.38 29.43
Q2 2023 44.85 4.51 4.51 29.49

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2014 29.41 29.41 3.56
Q2 2014 32.48 32.48 4.14
Q3 2014 32.55 32.55 4.11
Q4 2014 26.03 26.03 2.94
Q1 2015 30.88 30.88 3.21
Q2 2015 28.44 28.44 3.44
Q3 2015 22.37 22.37 2.74
Q4 2015 19.04 19.04 2.77
Q1 2016 16.69 16.69 2.46
Q2 2016 18.71 18.71 3.02
Q3 2016 15.98 15.98 2.54
Q4 2016 58.81 35.19 3.27
Q1 2017 73.26 36.05 2.60
Q2 2017 NEG 79.11 2.25
Q3 2017 NEG 69.35 1.87
Q4 2017 22.90 22.57 1.98
Q1 2018 26.45 26.11 2.51
Q2 2018 27.67 27.32 2.72
Q3 2018 25.44 25.05 2.07
Q4 2018 36.28 36.28 2.26
Q1 2019 31.56 31.56 2.05
Q2 2019 43.34 43.34 2.62
Q3 2019 37.22 37.22 2.40
Q4 2019 27.22 27.22 2.11
Q1 2020 19.53 19.53 1.53
Q2 2020 19.83 19.83 1.88
Q3 2020 26.08 26.08 2.43
Q4 2020 24.62 24.62 2.31
Q1 2021 24.08 24.08 2.24
Q2 2021 29.10 29.10 2.88
Q3 2021 23.12 23.12 2.58
Q4 2021 20.59 20.59 2.50
Q1 2022 28.53 28.53 3.23
Q2 2022 17.07 17.07 2.10
Q3 2022 21.46 21.46 2.72
Q4 2022 19.49 19.49 2.62
Q1 2023 20.60 20.60 3.07
Q2 2023 28.53 28.53 4.36

Business Segments (Million)

Compared With The
Period Medical Services Pharmacies
Q1 2014 149.16 32.67
Q2 2014 149.31 30.43
Q3 2014 149.57 27.87
Q4 2014 161.93 33.06
Q1 2015 184.80 34.63
Q2 2015 196.41 31.45
Q3 2015 180.37 30.41
Q4 2015 191.80 28.80
Q1 2016 220.78 33.16
Q2 2016 230.14 29.62
Q3 2016 173.08 23.93
Q4 2016 162.66 27.28
Q1 2017 176.04 26.40
Q2 2017 190.13 26.41
Q3 2017 185.07 23.27
Q4 2017 202.08 25.76
Q1 2018 183.47 23.20
Q2 2018 175.85 23.20
Q3 2018 155.67 20.74
Q4 2018 154.94 26.74
Q1 2019 157.71 21.72
Q2 2019 149.87 20.07
Q3 2019 153.76 19.76
Q4 2019 162.79 22.72
Q1 2020 170.81 24.20
Q2 2020 164.47 21.52
Q3 2020 187.44 25.56
Q4 2020 192.76 22.19
Q1 2021 188.50 25.70
Q2 2021 178.18 24.30
Q3 2021 187.54 25.57
Q4 2021 188.78 26.82
Q1 2022 169.18 42.30
Q2 2022 207.43 9.06
Q3 2022 209.69 28.59
Q4 2022 221.11 30.57
Q1 2023 230.03 31.37
Q2 2023 215.77 29.42

Analysts Estimates (Million)

Item Q2 2023 (e) Q2 2023 (a) Change‬
Average 53.30 47.80 (10.3 %)

Estimates vs Actual (Million)

Item Q2 2023 (e) Q2 2023 (a) Change
Al Rajhi Capital 47.00 47.80 1.7 %
HSBC 52.00 47.80 (8.1) %
AlJazira Capital 52.30 47.80 (8.6) %
Hermes 55.00 47.80 (13.1) %
OSOOL AND BAKHEET 60.20 47.80 (20.6) %

Current
Market Cap (M Riyal) 9,319.83
Enterprise Value (EV) (M) 9,016.84
Shares Outstanding ((M)) 44.85
EPS ( Riyal) (TTM) 5.93
Book Value (BV) ( Riyal) 34.22
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 37.26
P/E (TTM) 35.04
Price/book 6.07
Return on Average Assets (%) (TTM) 13.2
Return on Average Equity (%) (TTM) 18.6

Share Price

208.00
(1.00) (0.48 %)

National Medical Care Co. (CARE)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.